Related Experiment Video
Updated: Jul 13, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions
1IVC Evidensia Small Animal Clinic Hofheim, 65719 Hofheim am Taunus, Germany.
Abstract:
Tyrosine kinase inhibitors (TKIs) have become invaluable in the treatment of human and canine malignancies, but their role in feline oncology is less defined. While toceranib phosphate and masitinib mesylate are licensed for use in dogs, no TKI is yet approved for cats. This review systematically maps the research conducted on the expression of tyrosine kinases in neoplastic and non-neoplastic domestic feline tissues, as well as the in vitro/in vivo use of TKIs in domestic cats. We identify and discuss knowledge gaps and speculate on the further research and potential indications for TKI use in cats. A comprehensive search of three electronic databases and relevant paper reference lists identified 139 studies meeting the inclusion criteria. The most commonly identified tumors were mast cell tumors (MCTs), mammary and squamous cell carcinomas and injection-site sarcomas. Based on the current literature, toceranib phosphate appears to be the most efficacious TKI in cats, especially against MCTs. Exploring the clinical use of TKIs in mammary carcinomas holds promise. Despite the progress, currently, the evidence falls short, underscoring the need for further research to discover new indications in feline oncology and to bridge the knowledge gaps between human and feline medicine.
Insights
Tyrosine kinase inhibitors (TKIs) show promise in feline oncology, particularly toceranib phosphate for mast cell tumors. Further research is needed to expand TKI applications and address knowledge gaps in cat cancer treatment.
Area of Science:
- Veterinary Oncology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) are established in human and canine cancer therapy.
- Their application in feline oncology remains limited, with no TKIs currently approved for cats.
Purpose of the Study:
- To systematically review research on tyrosine kinase expression in feline tissues.
- To evaluate the in vitro and in vivo use of TKIs in domestic cats.
- To identify knowledge gaps and potential future indications for TKIs in feline cancer.
Main Methods:
- A comprehensive literature search of three electronic databases and reference lists.
- Inclusion criteria identified 139 relevant studies.
- Analysis focused on tyrosine kinase expression and TKI efficacy in feline neoplastic and non-neoplastic tissues.
Main Results:
- Commonly studied feline tumors include mast cell tumors (MCTs), mammary carcinomas, squamous cell carcinomas, and injection-site sarcomas.
- Toceranib phosphate demonstrated the most efficacy, particularly against feline MCTs.
- Mammary carcinomas show potential for TKI treatment.
Conclusions:
- Toceranib phosphate is currently the most promising TKI for feline cancers, especially MCTs.
- Further research is crucial to establish new indications and bridge knowledge gaps in feline oncology.
- Clinical trials are needed to validate TKI efficacy and safety in cats.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...